/PRNewswire/ "The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6.
EQS-News: Swedish Electromagnet Invest AB (Publ) / Key word(s): Interim Report Swedish Electromagnet Invest AB (Publ): Year-End Report January - December 2022 28.02.2023 / 17:00 CET/CEST The
EQS-News: Swedish Electromagnet Invest AB (Publ) / Key word(s): Interim Report Swedish Electromagnet Invest AB (Publ) : Year-End Report January – December 2022 28.02.2023 / 17:00 CET/CEST The issuer is solely responsible for the content of this announcement. Swedish Electromagnet Invest AB (publ.
/PRNewswire/ Catena Media plc Year-end Report January – December 2022 Highlights Revenue increased by 31 percent in North America in Q4, led by the launch.